Literature DB >> 7288483

The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication.

A Waxman, L Ramanna, N Chapman, D Chapman, M Brachman, D Tanasescu, D Berman, B Catz, G Braunstein.   

Abstract

Twenty-four patients with differentiated thyroid cancer were studied with diagnostic I-131 neck chest scans after having undergone bilateral subtotal thyroidectomy and initial I-131 therapy with either 30- or 100-mCi doses. With an endogenous stimulation protocol, follow-up studies were performed with neck and chest scans using 2 and 10 mCi I-131. A 400% increase in sensitivity was found with a 10-mCi dose relative to a 2-mCi dose. Comparison with therapeutic doses of 30 and 100 mCi resulted in further increases in the detection of residual iodine-avid tissue. We conclude that a 2-mCi or lower dose of I-131 is inadequate in evaluating residual iodine-avid tissue visually in patients with thyroid cancer. The study does not answer the critical question of whether it is necessary to treat a patient presenting a negative 2-mCi but a positive 10-mCi scan. It may be appropriate to define ablation visually as well as clinically, with further studies directed toward determining a treatment rationale in this patient population.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7288483

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Post-operative diagnosis and therapy of thyroid carcinoma by nuclear medicine.

Authors:  H Hundeshagen
Journal:  Eur J Nucl Med       Date:  1983

2.  Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up.

Authors:  Frank Berger; Ulla Friedrich; Peter Knesewitsch; Klaus Hahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-18       Impact factor: 9.236

Review 3.  False positive diagnosis on (131)iodine whole-body scintigraphy of differentiated thyroid cancers.

Authors:  Vincenzo Triggiani; Vito Angelo Giagulli; Michele Iovino; Giovanni De Pergola; Brunella Licchelli; Antonio Varraso; Franca Dicembrino; Guido Valle; Edoardo Guastamacchia
Journal:  Endocrine       Date:  2015-10-26       Impact factor: 3.633

4.  Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases.

Authors:  Levent Kabasakal; Nalan Alan Selçuk; Hojjet Shafipour; Ozlem Ozmen; Cetin Onsel; Ilhami Uslu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

5.  Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma.

Authors:  A J Brendel; B Lambert; M Guyot; R Jeandot; H Dubourg; P Roger; S Wynchauk; G Manciet; G Lefort
Journal:  Eur J Nucl Med       Date:  1990

6.  Thyrotropin variations may explain some positive radioiodine therapy scans in patients with negative diagnostic scans.

Authors:  P Zanotti-Fregonara; I Keller; D Rubello; M Calzada-Nocaudie; J Y Devaux; E Hindié
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

7.  The diagnostic value of 124I-PET in patients with differentiated thyroid cancer.

Authors:  Ha T T Phan; Pieter L Jager; Anne M J Paans; John T M Plukker; M G G Sturkenboom; W J Sluiter; Bruce H R Wolffenbuttel; Rudi A J O Dierckx; Thera P Links
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-04       Impact factor: 9.236

Review 8.  Radioactive Iodine Therapy and Glucose Tolerance.

Authors:  Roghaieh Samadi; Babak Shafiei; Fereidoun Azizi; Asghar Ghasemi
Journal:  Cell J       Date:  2017-02-22       Impact factor: 2.479

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.